Evidence-Based Medicine and Rare Diseases

被引:10
|
作者
Day, Simon [1 ]
机构
[1] Roche Prod Ltd, Welwyn Garden City AL7 1TW, Herts, England
来源
RARE DISEASES EPIDEMIOLOGY | 2010年 / 686卷
关键词
Bias; Bradford Hill; Evidence; Meta-analysis; Patient preference; Precision; SMALL CLINICAL-TRIALS; 1ST PATIENT; THERAPIES; RANDOMIZE; APPROVAL; STROKE; RISKS; DRUGS; RATES; ISNT;
D O I
10.1007/978-90-481-9485-8_3
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This chapter discusses the meaning of evidence-based medicine and where it relates to randomised controlled trials, but also where it does not. The need for good quality evidence is stressed through a discussion of high failure rates in drug development and arguments against access to unlicensed (and largely untested) treatments are set out (despite the good intentions of those who advocate such access to treatments). Good quality, reliable evidence does not always have to come from clinical trials. Other forms of evidence are discussed. Meta-analyses of individual trials may help to resolve the problem that, in rare diseases, it may be very difficult or impossible to do adequately powered clinical trials - but that does not imply those trials have no value at all. The importance of patients' choices is stressed but the difficulties of making choices and the general poor understanding of risk makes patients very vulnerable to making poor decisions. They need to be adequately guided through the evidence to make proper informed decisions.
引用
收藏
页码:41 / 53
页数:13
相关论文
共 50 条
  • [1] EVIDENCE-BASED MEDICINE AND RARE DISEASES
    Roldan, Emilio J. A.
    [J]. ACTUALIZACIONES EN OSTEOLOGIA, 2015, 11 (02) : 186 - 186
  • [2] Evidence-Based Medicine and Rare Diseases
    Day, Simon
    [J]. RARE DISEASES EPIDEMIOLOGY: UPDATE AND OVERVIEW, 2ND EDITION, 2017, 1031 : 207 - 220
  • [3] Infectious diseases evidence assessments: evidence-based medicine in practice
    Misasi, John N.
    Nakamura, Mari M.
    [J]. MEDICAL EDUCATION, 2013, 47 (11) : 1123 - 1124
  • [4] Evidence-based medicine and outcomes research in infectious diseases
    Ledger, WJ
    [J]. INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1998, 7 (03) : 148 - 151
  • [5] Evidence in Medicine and Evidence-Based Medicine
    Worrall, John
    [J]. PHILOSOPHY COMPASS, 2007, 2 (06): : 981 - 1022
  • [6] Evidence-based medicine and evidence-based guidelines
    Sekimoto, Miho
    Imanaka, Yuichi
    [J]. PANCREAS, 2007, 35 (01) : 87 - 88
  • [7] Evidence-based retrieval in evidence-based medicine
    Patrick, TB
    Demiris, G
    Folk, LC
    Moxley, DE
    Mitchell, JA
    Tao, DH
    [J]. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 2004, 92 (02) : 196 - 199
  • [8] Navigating the uncommon: challenges in applying evidence-based medicine to rare diseases and the prospects of artificial intelligence solutions
    Rennie, Olivia
    [J]. MEDICINE HEALTH CARE AND PHILOSOPHY, 2024, 27 (03) : 269 - 284
  • [9] Botulinum toxin: evidence-based medicine criteria in rare indications
    Wolfgang H. Jost
    André Kohl
    [J]. Journal of Neurology, 2001, 248 (Suppl 1) : I39 - I44
  • [10] Botulinum toxin: evidence-based medicine criteria in rare indications
    Jost, WH
    Kohl, A
    [J]. JOURNAL OF NEUROLOGY, 2001, 248 : S39 - S44